TICKERNERD
Menu
WHWKWHWKHealthcare · Biotechnology

WHWK Stock Forecast: Whitehawk Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.74
−1.86% on the day

The 8 Wall Street analysts covering Whitehawk Therapeutics, Inc. hold a median 12-month price target of $7.5 — +58.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$269.7M
Ticker Nerd rank
73 / 100
Median analyst target
$7.50
Analysts covering
8
Total return, dividends reinvested
1W
+6.3%
1M
+21.2%
YTD
+95.9%
1Y
+187.3%
From 52W high
−7.1%
From 52W low
+187.3%
$1.65
$5.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WHWK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Whitehawk Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Revisions
74
Accruals
66
Size
64
Quality
63
Volatility
61
Value
43
Growth
41
Issuance
34

Momentum (94): The shares have been drifting up relative to others.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WHWK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WHWK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26WHWKHigh $10.00Median $7.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
5 Buy3 Hold0 Sell
Low $4.00Median $7.50High $10.00

The green dot is the last close — the median target sits +58.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026Leerink PartnersInitiatesOutperform$9.00
25 June 2026B. Riley SecuritiesInitiatesBuy—
16 Apr 2026CitizensInitiatesMarket Outperform—
22 Dec 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WHWK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

WHWK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Whitehawk Therapeutics, Inc. (WHWK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 55% of US stocks

Price / sales
37.7×

Cheaper than 7% of US stocks

Price / book
1.9×

Cheaper than 49% of US stocks

EV / EBITDA
−0.9×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−288.3%

Higher than 9% of US stocks

Net margin
89.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−45.0%

Higher than 23% of US stocks

Return on assets
−28.7%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

WHWK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
WHWKWhitehawk Therapeutics, Inc.$269.7M
73
LCTXLineage Cell Therapeutics, Inc.$269.0M
56
FATEFate Therapeutics, Inc.$270.9M
93
SRZNSurrozen, Inc.$275.6M
77
TTRXTurn Therapeutics, Inc.$278.6M
17
MGNXMacroGenics, Inc.$260.6M
67
ELDNEledon Pharmaceuticals, Inc.$280.4M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Whitehawk Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WHWK news & analysis

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

PRNewsWire · 6 Aug 2026positive

Whitehawk Therapeutics reported its second quarter 2026 financial results, with $190.0 million in cash, cash equivalents, and short-term investments as of June 30, 2026, anticipated to fund operations into the second half of 2028. The company noted that Phase 1 trials for HWK-007 and HWK-016 continue to enroll, and the Phase 1 trial for HWK-206 remains on track to initiate in Q3 2026.

Why it matters — The update confirms continued clinical trial progress across its pipeline and a cash runway into 2H 2028, key indicators of near-term operational stability for WHWK investors.

FAQ

Frequently asked questions about WHWK stock

What is the WHWK stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Whitehawk Therapeutics, Inc. have a median 12-month price target of $7.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WHWK stock a buy right now?

Of the 8 analysts covering Whitehawk Therapeutics, Inc., 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Whitehawk Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WHWK?

As at 22 Aug 2026, Whitehawk Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will WHWK stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +58.2% from the last close, and Ticker Nerd's factor model ranks Whitehawk Therapeutics, Inc. 73 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WHWK stock forecast for 2030?

No analyst covering Whitehawk Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WHWK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has WHWK stock performed over the past year?

Whitehawk Therapeutics, Inc. returned +187.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Whitehawk Therapeutics, Inc. do?

Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer.

What is the latest news on WHWK?

The most recent item we track (PRNewsWire, 6 Aug 2026): "Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights". Whitehawk Therapeutics reported its second quarter 2026 financial results, with $190.0 million in cash, cash equivalents, and short-term investments as of June 30, 2026, anticipated to fund operations into the second half of 2028. The company noted that Phase 1 trials for HWK-007 and HWK-016 continue to enroll, and the Phase 1 trial for HWK-206 remains on track to initiate in Q3 2026.

Company

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer. The company’s primary objective is to leverage next-generation ADC platform technologies—engineered for greater stability and a higher therapeutic index—to address the needs of patients with challenging, treatment-resistant tumors. Its pipeline comprises three ADC assets, each designed to target clinically validated proteins that are broadly expressed across various tumor types, with a strategic emphasis on lung and gynecological cancers. Whitehawk Therapeutics employs advanced tumor biology insights to more effectively dose and deliver their therapies, aiming to overcome limitations found in earlier ADC approaches. Formerly operating under the name Aadi Bioscience, the company relaunched with a sharpened focus in March 2025, reflecting its commitment to innovation in cancer treatment. Headquartered in Morristown, New Jersey, Whitehawk Therapeutics occupies a significant niche within the healthcare and biotechnology sectors, serving as a key player in the advancement of targeted cancer therapies for patients with significant unmet medical needs.

CEO Dr. David J. Lennon Ph.D. · 32 employees · United States · https://ir.whitehawktx.com